Pharmaceutical giant Pfizer has finalized a deal to secure up to $1.5 billion in funding from Blackstone. The capital is earmarked for the development of the company's obesity drug, berobenatide.
Under the terms of the agreement, Blackstone is entitled to receive milestone-based payments. However, the firm will not acquire any ownership rights or intellectual property related to the drug.